Advertisement
Canada markets open in 2 hours 26 minutes
  • S&P/TSX

    22,107.08
    +194.56 (+0.89%)
     
  • S&P 500

    5,248.49
    +44.91 (+0.86%)
     
  • DOW

    39,760.08
    +477.75 (+1.22%)
     
  • CAD/USD

    0.7355
    -0.0017 (-0.24%)
     
  • CRUDE OIL

    82.17
    +0.82 (+1.01%)
     
  • Bitcoin CAD

    96,183.12
    +810.08 (+0.85%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • GOLD FUTURES

    2,233.30
    +20.60 (+0.93%)
     
  • RUSSELL 2000

    2,114.35
    +44.19 (+2.13%)
     
  • 10-Yr Bond

    4.1960
    0.0000 (0.00%)
     
  • NASDAQ futures

    18,500.00
    -3.75 (-0.02%)
     
  • VOLATILITY

    13.00
    +0.22 (+1.72%)
     
  • FTSE

    7,958.37
    +26.39 (+0.33%)
     
  • NIKKEI 225

    40,168.07
    -594.66 (-1.46%)
     
  • CAD/EUR

    0.6813
    +0.0008 (+0.12%)
     

Obalon Announces Third Quarter 2020 Financial Results

SAN DIEGO, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced its financial results for the third quarter ended September 30, 2020.

Financial results for the third quarter of 2020

Revenue for the third quarter of 2020 was $44,000, compared to $0.3 million for the third quarter of 2019, with the decrease primarily due to the suspension of operations in the second quarter of 2020. Net loss for the third quarter of 2020 was $1.6 million, compared to $3.7 million for the third quarter of 2019. Net loss per share for the third quarter of 2020 was $0.20, compared to $0.61 for the third quarter of 2019.

Cost of revenue was $41,000 for the third quarter of 2020, down from $0.4 million for the third quarter of 2019. Gross profit for the third quarter of 2020 was $3,000 compared to a gross deficit of $0.1 million for the third quarter of 2019.

ADVERTISEMENT

Research and Development expense for the third quarter of 2020 totaled $0.3 million, down from $1.2 million for the third quarter of 2019. Selling, General and Administrative expense decreased to $1.3 million for the third quarter of 2020, compared to $2.5 million for the third quarter of 2019.

Operating loss for the third quarter of 2020 was $1.6 million, down from a loss of $3.7 million for the third quarter of 2019.

As of September 30, 2020, the Company had cash and cash equivalents of $5.5 million and $0.4 million of debt related to its Payroll Protection Program loan. The Company intends to continue exploring the potential for third-party reimbursement for the Obalon Balloon System, as well as exploring and evaluating financial alternatives to help meet its capital needs and strategic alternatives that might enhance stockholder value. There is no assurance that any financial or strategic alternative will be identified. If the Company is not able to raise additional capital to meet its needs or to identify a suitable strategic alternative, it will have to discontinue all operations and may be required to declare bankruptcy or dissolve.

About Obalon Therapeutics, Inc.
Obalon Therapeutics, Inc. (NASDAQ:OBLN) is a San Diego-based company focused on developing and commercializing novel technologies for weight loss.

Cautionary Statement Regarding Forward Looking Statements

This press release contains forward-looking statements that are not purely historical regarding Obalon’s or its management’s intentions, beliefs, expectations and strategies for the future, including those related to new products and their potential benefits. All forward-looking statements and reasons why results might differ included in this press release are made as of the date of this release, based on information currently available to Obalon, deal with future events, are subject to various risks and uncertainties, and actual results could differ materially from those anticipated in those forward looking statements. The risks and uncertainties that may cause actual results to differ materially from Obalon’s current expectations are more fully described in Obalon’s annual report on Form 10-K for the period ended December 31, 2019, periodic reports on Form 10-Q for the periods ended September 30, 2020, June 30, 2020 and March 31, 2020 and its other reports, each as filed with the Securities and Exchange Commission. Except as required by law, Obalon assumes no obligation to update any such forward-looking statement after the date of this report or to conform these forward-looking statements to actual results.

OBALON THERAPEUTICS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(unaudited)
(in thousands, except shares and per share data)

Three Months Ended September 30,

Nine Months Ended September 30,

2020

2019

2020

2019

Revenue

$

44

$

333

$

1,527

$

2,494

Cost of revenue

41

412

1,005

2,323

Gross profit (deficit)

3

(79

)

522

171

Operating expenses:

Research and development

271

1,174

2,293

5,401

Selling, general and administrative

1,291

2,489

7,546

13,025

Asset impairment and other charges

1,310

Total operating expenses

1,562

3,663

11,149

18,426

Loss from operations

(1,559

)

(3,742

)

(10,627

)

(18,255

)

Interest (expense) income, net

(1

)

37

29

(448

)

Other expense, net

(1

)

(411

)

(60

)

Net loss and comprehensive loss

$

(1,560

)

$

(3,706

)

$

(11,009

)

$

(18,763

)

Net loss per share, basic and diluted

$

(0.20

)

$

(0.61

)

$

(1.42

)

$

(5.07

)

Weighted-average common shares outstanding, basic and diluted

7,728,639

6,061,248

7,727,494

3,700,538

OBALON THERAPEUTICS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except shares and par value data)

September 30,
2020

December 31,
2019

Assets

(unaudited)

Current assets:

Cash and cash equivalents

$

5,514

$

14,055

Accounts receivable, net

285

Inventory

1,936

Other current assets

3,517

1,959

Total current assets

9,031

18,235

Property and equipment, net

982

1,081

Lease right-of-use assets

646

1,077

Other long-term assets

1,303

Total assets

$

11,962

$

20,393

Liabilities and Stockholders’ Equity

Current liabilities:

Accounts payable

$

656

$

648

Accrued compensation

116

820

Deferred revenue

61

424

Other current liabilities

3,634

1,524

Current portion of lease liabilities

583

561

Total current liabilities

5,050

3,977

Lease liabilities, long-term

553

567

Long-term debt

430

Other long-term liabilities

7

Total long-term liabilities

990

567

Total liabilities

6,040

4,544

Commitments and contingencies

Stockholders’ equity:

Common stock, $0.001 par value; 100,000,000 shares authorized as of September 30, 2020 and December 31, 2019; 7,770,698 and 7,724,100 shares issued and outstanding as of September 30, 2020 and December 31, 2019, respectively

8

8

Additional paid-in capital

189,353

188,271

Accumulated deficit

(183,439

)

(172,430

)

Total stockholders’ equity

5,922

15,849

Total liabilities and stockholders’ equity

$

11,962

$

20,393

OBALON THERAPEUTICS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)
(in thousands)

Nine Months Ended September 30,

2020

2019

Operating activities:

Net loss

$

(11,009

)

$

(18,763

)

Adjustments to reconcile net loss to net cash used in operating activities:

Depreciation

260

361

Stock-based compensation

1,021

2,300

Issuance of cash-settled options

7

Issuance of warrants for the purchase of common stock

45

Loss on disposal of fixed assets

128

Amortization of right-of-use assets

378

301

Accretion of investment discount, net

(2

)

Amortization of debt discount

70

Impairment of long-lived assets and other charges

1,257

Impairment of inventory

53

Change in operating assets and liabilities:

Accounts receivable, net

285

632

Inventory

(524

)

(117

)

Other long-term assets

(9

)

Other current assets

(1,389

)

1,604

Accounts payable

8

(724

)

Accrued compensation

(688

)

(3,097

)

Deferred revenue

(363

)

(69

)

Lease liabilities, net

(293

)

(248

)

Other current and long term liabilities

2,107

(363

)

Net cash used in operating activities

(8,854

)

(17,987

)

Investing activities:

Maturities of short-term investments

2,550

Purchase of property and equipment

(117

)

(44

)

Net cash (used in) provided by investing activities

(117

)

2,506

Financing activities:

Proceeds from long-term loan

430

10,000

Payment on long-term loan

(20,000

)

Proceeds from issuance of common and warrants, net of paid issuance costs

15,014

Proceeds from issuance of common stock, net of issuance costs

8,659

Proceeds from sale of common stock upon exercise of stock options

1

Net cash provided by financing activities

430

13,674

Net decrease in cash and cash equivalents

(8,541

)

(1,807

)

Cash and cash equivalents at beginning of period

14,055

21,187

Cash and cash equivalents at end of period

$

5,514

$

19,380

Supplemental cash flow information:

Interest paid

$

$

700

Unpaid issuance costs

$

$

295


CONTACT: For Obalon Therapeutics, Inc. Investor Contact: Andrew Rasdal President and Chief Executive Officer Obalon Therapeutics, Inc. Office: +1 844 362 2566 arasdal@obalon.com